Relation of @entity414 with components of @entity209 before and after Roux-en-Y gastric bypass in morbidly XXXX subjects.

@entity1 @entity101 @entity6 @entity28 @entity353 @entity1674 @entity5052 @entity209 @entity413 @entity414
OBJECTIVE: The purpose of the study was to investigate the prevalence of @entity5052 in morbidly @entity28 subjects before and after Roux-en-Y gastric bypass (RYGBP) and its relationship with @entity209 . SUBJECTS AND METHOD: We evaluated 420 morbidly @entity28 @entity1 . Pre and postoperative (8 months after RYGBP) blood samples were drawn. @entity28 @entity1 underwent laparoscopic RYGBP and after eight months all the tests were repeated. RESULTS: The overall prevalence of @entity5052 was 34.28%. @entity5052 was more common in @entity1 than in @entity1 (51.72 vs. 29.72%; p = 0.0002). @entity1 with @entity5052 were more likely to have @entity6 (p = 0.034) and more elevated fasting plasma @entity413 levels (p = 0.027). @entity1 with @entity5052 were more likely to have @entity101 (p = 0.003), @entity209 (p = 0.001), elevated @entity1674 (p = 0.001) and GGT (p = 0.009), and decreased HDL (p = 0.011). After surgery, @entity414 levels decreased from 5.60    1.28 to 4.23    1.20 (p < 0.0001). The prevalence of @entity5052 decreased from 33.6% to 6.4% (p < 0.0001), in @entity1 from 48.3% to 17.2% (p < 0.0001) and in @entity1 from 29.7% to 3.6% (p < 0.0001). CONCLUSION: Concentrations of @entity414 were associated with the prevalence of @entity209 in this sample of morbidly @entity28 @entity1 . Also, @entity353 after RYGBP can reduce @entity414 levels and the prevalence of @entity5052 .
